1-11 of 11
Ying Chen
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Determinants of Response to Talazoparib in Patients with HER2-Negative, Germline BRCA1/2-Mutated Breast Cancer

Joanne L. Blum, A. Douglas Laird, Jennifer K. Litton, Hope S. Rugo, Johannes Ettl, Sara A. Hurvitz, Miguel Martin, Henri H. Roché, Kyung-Hun Lee, Annabel Goodwin, Ying Chen, Silvana Lanzalone, Jijumon Chelliserry, Akos Czibere, Julia F. Hopkins, Lee A. Albacker, Lida A. Mina
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (7): 1383–1390.
https://doi.org/10.1158/1078-0432.CCR-21-2080
Published: 01 April 2022
View article titled, Determinants of Response to Talazoparib in Patients with HER2-Negative, Germline <em>BRCA1/2</em>-Mutated Breast Cancer
Open the PDF for Determinants of Response to Talazoparib in Patients with HER2-Negative, Germline <em>BRCA1/2</em>-Mutated Breast Cancer in another window
Includes: Supplementary data
Journal Articles

First-in-Human Study of Utomilumab, a 4-1BB/CD137 Agonist, in Combination with Rituximab in Patients with Follicular and Other CD20+ Non-Hodgkin Lymphomas

Ajay K. Gopal, Ronald Levy, Roch Houot, Sandip P. Patel, Leslie Popplewell, Caron Jacobson, Xinmeng J. Mu, Shibing Deng, Keith A. Ching, Ying Chen, Craig B. Davis, Bo Huang, Kolette D. Fly, Aron Thall, Adrian Woolfson, Nancy L. Bartlett
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2020) 26 (11): 2524–2534.
https://doi.org/10.1158/1078-0432.CCR-19-2973
Published: 01 June 2020
View article titled, First-in-Human Study of Utomilumab, a 4-1BB/CD137 Agonist, in Combination with Rituximab in Patients with Follicular and Other CD20<sup>+</sup> Non-Hodgkin Lymphomas
Open the PDF for First-in-Human Study of Utomilumab, a 4-1BB/CD137 Agonist, in Combination with Rituximab in Patients with Follicular and Other CD20<sup>+</sup> Non-Hodgkin Lymphomas in another window
Includes: Supplementary data
Journal Articles

Zinc Metallochaperones Reactivate Mutant p53 Using an ON/OFF Switch Mechanism: A New Paradigm in Cancer Therapeutics

Xin Yu, Samuel Kogan, Ying Chen, Ashley T. Tsang, Tracy Withers, Hongxia Lin, John Gilleran, Brian Buckley, Dirk Moore, Joseph Bertino, Chang Chan, S. David Kimball, Stewart N. Loh, Darren R. Carpizo
Journal: Clinical Cancer Research
Clin Cancer Res (2018) 24 (18): 4505–4517.
https://doi.org/10.1158/1078-0432.CCR-18-0822
Published: 14 September 2018
View article titled, Zinc Metallochaperones Reactivate Mutant p53 Using an ON/OFF Switch Mechanism: A New Paradigm in Cancer Therapeutics
Open the PDF for Zinc Metallochaperones Reactivate Mutant p53 Using an ON/OFF Switch Mechanism: A New Paradigm in Cancer Therapeutics in another window
Includes: Supplementary data
Journal Articles

Phase I Study of Single-Agent Utomilumab (PF-05082566), a 4-1BB/CD137 Agonist, in Patients with Advanced Cancer

Neil H. Segal, Aiwu R. He, Toshihiko Doi, Ronald Levy, Shailender Bhatia, Michael J. Pishvaian, Rossano Cesari, Ying Chen, Craig B. Davis, Bo Huang, Aron D. Thall, Ajay K. Gopal
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2018) 24 (8): 1816–1823.
https://doi.org/10.1158/1078-0432.CCR-17-1922
Published: 12 April 2018
View article titled, Phase I Study of Single-Agent Utomilumab (PF-05082566), a 4-1BB/CD137 Agonist, in Patients with Advanced Cancer
Open the PDF for Phase I Study of Single-Agent Utomilumab (PF-05082566), a 4-1BB/CD137 Agonist, in Patients with Advanced Cancer in another window
Includes: Supplementary data
Journal Articles

Phase Ib Study of Utomilumab (PF-05082566), a 4-1BB/CD137 Agonist, in Combination with Pembrolizumab (MK-3475) in Patients with Advanced Solid Tumors

Anthony W. Tolcher, Mario Sznol, Siwen Hu-Lieskovan, Kyriakos P. Papadopoulos, Amita Patnaik, Drew W. Rasco, Donna Di Gravio, Bo Huang, Dhiraj Gambhire, Ying Chen, Aron D. Thall, Nuzhat Pathan, Emmett V. Schmidt, Laura Q.M. Chow
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2017) 23 (18): 5349–5357.
https://doi.org/10.1158/1078-0432.CCR-17-1243
Published: 14 September 2017
View article titled, Phase Ib Study of Utomilumab (PF-05082566), a 4-1BB/CD137 Agonist, in Combination with Pembrolizumab (MK-3475) in Patients with Advanced Solid Tumors
Open the PDF for Phase Ib Study of Utomilumab (PF-05082566), a 4-1BB/CD137 Agonist, in Combination with Pembrolizumab (MK-3475) in Patients with Advanced Solid Tumors in another window
Includes: Supplementary data
Journal Articles

Inhibition of the Nuclear Export Receptor XPO1 as a Therapeutic Target for Platinum-Resistant Ovarian Cancer

Ying Chen, Sandra Catalina Camacho, Thomas R. Silvers, Albiruni R.A. Razak, Nashat Y. Gabrail, John F. Gerecitano, Eva Kalir, Elena Pereira, Brad R. Evans, Susan J. Ramus, Fei Huang, Nolan Priedigkeit, Estefania Rodriguez, Michael Donovan, Faisal Khan, Tamara Kalir, Robert Sebra, Andrew Uzilov, Rong Chen, Rileen Sinha, Richard Halpert, Jean-Noel Billaud, Sharon Shacham, Dilara McCauley, Yosef Landesman, Tami Rashal, Michael Kauffman, Mansoor R. Mirza, Morten Mau-Sørensen, Peter Dottino, John A. Martignetti
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2017) 23 (6): 1552–1563.
https://doi.org/10.1158/1078-0432.CCR-16-1333
Published: 14 March 2017
View article titled, Inhibition of the Nuclear Export Receptor XPO1 as a Therapeutic Target for Platinum-Resistant Ovarian Cancer
Open the PDF for Inhibition of the Nuclear Export Receptor XPO1 as a Therapeutic Target for Platinum-Resistant Ovarian Cancer in another window
Includes: Supplementary data
Journal Articles

Tumor-associated Lymphatic Endothelial Cells Promote Lymphatic Metastasis By Highly Expressing and Secreting SEMA4C

Jun-Cheng Wei, Jie Yang, Dan Liu, Ming-Fu Wu, Long Qiao, Jun-Nai Wang, Quan-Fu Ma, Zhen Zeng, Shuang-Mei Ye, En-Song Guo, Xue-Feng Jiang, Lan-Ying You, Ying Chen, Li Zhou, Xiao-Yuan Huang, Tao Zhu, Li Meng, Jian-Feng Zhou, Zuo-Hua Feng, Ding Ma, Qing-Lei Gao
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2017) 23 (1): 214–224.
https://doi.org/10.1158/1078-0432.CCR-16-0741
Published: 02 January 2017
View article titled, Tumor-associated Lymphatic Endothelial Cells Promote Lymphatic Metastasis By Highly Expressing and Secreting SEMA4C
Open the PDF for Tumor-associated Lymphatic Endothelial Cells Promote Lymphatic Metastasis By Highly Expressing and Secreting SEMA4C in another window
Includes: Supplementary data
Journal Articles

Real-time, Near-Infrared Fluorescence Imaging with an Optimized Dye/Light Source/Camera Combination for Surgical Guidance of Prostate Cancer

Brian P. Neuman, John B. Eifler, Mark Castanares, Wasim H. Chowdhury, Ying Chen, Ronnie C. Mease, Rong Ma, Amarnath Mukherjee, Shawn E. Lupold, Martin G. Pomper, Ronald Rodriguez
Journal: Clinical Cancer Research
Clin Cancer Res (2015) 21 (4): 771–780.
https://doi.org/10.1158/1078-0432.CCR-14-0891
Published: 16 February 2015
View article titled, Real-time, Near-Infrared Fluorescence Imaging with an Optimized Dye/Light Source/Camera Combination for Surgical Guidance of Prostate Cancer
Open the PDF for Real-time, Near-Infrared Fluorescence Imaging with an Optimized Dye/Light Source/Camera Combination for Surgical Guidance of Prostate Cancer in another window
Includes: Multimedia, Supplementary data
Journal Articles

IL-17A Stimulates the Progression of Giant Cell Tumors of Bone

Meng Xu, Zhi-Gang Song, Cheng-Xiong Xu, Guang-Hua Rong, Ke-Xing Fan, Ji-Ying Chen, Wei Zhang, Jin-Peng Jia, Gang Han, Wei Wang, Wei Chai, Wen-Tao Liang, Wen-Zhi Bi, Yan Wang
Journal: Clinical Cancer Research
Clin Cancer Res (2013) 19 (17): 4697–4705.
https://doi.org/10.1158/1078-0432.CCR-13-0251
Published: 02 September 2013
View article titled, IL-17A Stimulates the Progression of Giant Cell Tumors of Bone
Open the PDF for IL-17A Stimulates the Progression of Giant Cell Tumors of Bone in another window
Includes: Supplementary data
Journal Articles

2-(3-{1-Carboxy-5-[(6-[18F]Fluoro-Pyridine-3-Carbonyl)-Amino]-Pentyl}-Ureido)-Pentanedioic Acid, [18F]DCFPyL, a PSMA-Based PET Imaging Agent for Prostate Cancer

Ying Chen, Mrudula Pullambhatla, Catherine A. Foss, Youngjoo Byun, Sridhar Nimmagadda, Srinivasan Senthamizhchelvan, George Sgouros, Ronnie C. Mease, Martin G. Pomper
Journal: Clinical Cancer Research
Clin Cancer Res (2011) 17 (24): 7645–7653.
https://doi.org/10.1158/1078-0432.CCR-11-1357
Published: 18 December 2011
View article titled, 2-(3-{1-Carboxy-5-[(6-[<sup>18</sup>F]Fluoro-Pyridine-3-Carbonyl)-Amino]-Pentyl}-Ureido)-Pentanedioic Acid, [<sup>18</sup>F]DCFPyL, a PSMA-Based PET Imaging Agent for Prostate Cancer
Open the PDF for 2-(3-{1-Carboxy-5-[(6-[<sup>18</sup>F]Fluoro-Pyridine-3-Carbonyl)-Amino]-Pentyl}-Ureido)-Pentanedioic Acid, [<sup>18</sup>F]DCFPyL, a PSMA-Based PET Imaging Agent for Prostate Cancer in another window
Includes: Supplementary data
Journal Articles

Overexpression of Phosphorylated Mammalian Target of Rapamycin Predicts Lymph Node Metastasis and Prognosis of Chinese Patients with Gastric Cancer

Guanzhen Yu, Jiejun Wang, Ying Chen, Xi Wang, Jun Pan, Gang Li, Zhiliang Jia, Qiang Li, James C. Yao, Keping Xie
Journal: Clinical Cancer Research
Clin Cancer Res (2009) 15 (5): 1821–1829.
https://doi.org/10.1158/1078-0432.CCR-08-2138
Published: 27 February 2009
View article titled, Overexpression of Phosphorylated Mammalian Target of Rapamycin Predicts Lymph Node Metastasis and Prognosis of Chinese Patients with Gastric Cancer
Open the PDF for Overexpression of Phosphorylated Mammalian Target of Rapamycin Predicts Lymph Node Metastasis and Prognosis of Chinese Patients with Gastric Cancer in another window
Includes: Supplementary data